Gilead Sciences (GILD) to Resume Trading at 4:25PM ET Following Strong Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St rises as oil slide offers respite after Fed rate hike
- Oil falls 2% to one-week low as Middle East supply disruption fears ease
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Turkish Stocks Fall 6%, Triggering Market-wide Circuit Breaker - Bloomberg
About 9,000 Hep C patients have been cured with Sovaldi to date - Gilead (GILD)
July 23, 2014 4:48 PM EDTGilead Sciences (NASDAQ: GILD) said about 9,000 Hep C patients have been cured with Sovaldi to date
... MoreGilead Sciences, Inc. (GILD) Tops Q2 EPS by 63c; Boosts FY14 Revenue Outlook
July 23, 2014 4:07 PM EDTGilead Sciences, Inc. (NASDAQ: GILD) reported Q2 EPS of $2.36, $0.63 better than the analyst estimate of $1.73. Revenue for the quarter came in at $6.53 billion versus the consensus estimate of $5.68 billion.
During the second quarter, Gilead continued to make significant progress led by strong Sovaldi sales. Since Decembers launch, Sovaldi has been prescribed for more than 80,000 patients in the U.S. and Europe, underscoring the medical communitys recognition of the benefits of this product, said John C. Martin, PhD, Gileads Chairman and Chief Executive Officer. We look forward to making Sovaldi available in additional... More
